Skip to main content
. 2022 Jul 26;42(6):422–429. doi: 10.1111/cpf.12781

Table 1.

Participant characteristics

Mean ± SD ASD at baseline, n = 18 ASD dobutamine, n = 16 Controls at baseline, n = 16 Controls dobutamine, n= 16
Age (years) 51 ± 18** 50 ± 19 35 ± 13 35 ± 13
Sex (male/female) 5/13 4/12 13/3 13/3
BSA (m2) 1.9 ± 0.2 1.9 ± 0.2 1.9 ± 0.2 1.9 ± 0.2
Peak VO2 (ml/min/kg) 25 ± 6**** 46 ± 8
Peak VO2 (% of predicted) 102 ± 15**** 133 ± 21
HR (bpm) 73 ± 11* 123 ± 12*†††† 65 ± 10 134 ± 12††††
HR (% of predicted max) 73 ± 10 73 ± 10
SBP (mmHg) 124 ± 23** 147 ± 21††† 122 ± 11 158 ± 22††††
DBP (mmHg) 75 ± 16 78 ± 15 74 ± 10 87 ± 10†††
LV EDV (ml) 139 ± 32**** 126 ± 37** 186 ± 28 162 ± 26††
LV ESV (ml) 63 ± 19** 44 ± 17*†††† 81 ± 17 51 ± 13††††
LVSV (ml) 77 ± 18**** 82 ± 25*** 104 ± 16 110 ± 17††
LV EF (%) 55 ± 7 65 ± 8†††† 56 ± 5 68 ± 4††††
LV CO (L/min) 5.5 ± 1.4** 9.8 ± 2.7****†††† 7.0 ± 1.6 14.0 ± 1.6††††
LV CI (L/min/m2) 2.9 ± 0.5** 5.3 ± 1.1****†††† 3.6 ± 0.8 7.2 ± 0.9††††
RV EDV (ml) 323 ± 101*** 238 ± 91*†††† 212 ± 44 179 ± 33†††
RV ESV (ml) 160 ± 59*** 95 ± 51**†††† 97 ± 28 55 ± 12††††
RV SV (ml) 162 ± 50** 143 ± 56 115 ± 20 124 ± 25
RV EF (%) 51 ± 6* 61 ± 11**††† 56 ± 6 70 ± 4††††
RV CO (L/min) 11.7 ± 3.6*** 17.5 ± 6.8††† 7.7 ± 1.6 15.7 ± 2.5††††
RV CI (L/min/m2) 6.4 ± 2.2*** 9.7 ± 3.3†††† 4.0 ± 0.8 8.5 ± 1.5††††
Qp/Qs 1.9 ± 0.7 1.5 ± 0.5††

Note: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 ASD at rest versus controls at rest or ASD at stress vs controls at stress.

p < 0.05, †† p < 0.01, ††† p < 0.001, †††† p < 0.0001 ASD or controls at rest versus stress.

Abbreviations: ASD, atrial septal defect; BSA, body surface area; CI, cardiac index; CO, cardiac output; DBP, diastolic blood pressure; EDV, end‐diastolic volume; EF, ejection fraction; ESV, end‐systolic volume; HR, heart rate; LV, left‐ventricular; peak VO2, peak oxygen uptake; Qp/Qs, pulmonary flow/systemic flow; RV, right‐ventricular; SBP, systolic blood pressure; SD, standard deviation; SV, stroke volume.